| Website | leerink.com |
| @Leerink | |
| Phone | 617-248-1601 |
| webrequest@leerin... | |
| Employees | |
| Founded | 1995 |
Leerink Swann combines financial expertise and healthcare insight to enable clients to make the best-informed investment decisions. They use knowledge and abilities to advise clients on their healthcare investments, enhancing their fortunes and helping pave the way for future medical breakthroughs.
Single-Industry Focus The quality of understanding and perspectives is generated by single-industry focus in healthcare. As a result, clients who require success in the healthcare industry rely on Leerink Swann.
Exclusive Insights The insights come from two groups of specialists: investment professionals and more than 35,000-member MEDACorp network. The investment professionals apply their deep financial experience exclusively to the healthcare sector. MEDACorp delivers real-world answers about current and future developments on a wide range of healthcare topics. No other investment bank can boast the depth of expertise or ease of direct communication with network members that we can. The acumen and individualized attention make the value of knowledge unequalled.
Exceptional Decision Support By uniting the industry intelligence of investment bankers and strategic advisory team with the expert insight of MEDACorp, Leerink Swann offers compelling solutions and services available to investment managers and healthcare companies, allowing clients to be confident in their investment decisions.
Ideally Suited for Emerging Growth Leerink Swann’s unique business model makes us an outstanding partner to serve emerging-growth healthcare companies, as well as larger companies seeking to learn about the emerging growth space. They believe unique knowledge resources help companies devise and execute superior growth strategies. By activating domain expertise, Leerink Swann can optimize company positioning, identify and educate investors and uncover value-enhancing assets or merger partners - all with the goal of enhancing clients’ outcomes.
| Company | Date | Round | Size | Participants |
| Living Proof | 2/13 | Series C | $30M | 2 |
| Humedica | 10/09 | Series A | $30M | 4 |
